N/A
N=20
Effect of Local Anaesthetic Dilution on the Characteristics of Ultrasound Guided Axillary Brachial Plexus Block
Brachial Plexus Blockade
Bottom Line
View on ClinicalTrials.gov: NCT03207035 ↗Enrolled (actual)
20
Serious AEs
0.0%
Results posted
Oct 2021
Primary outcome: Primary: Onset of Axillary Block — 8.75; 6.25 minutes — p=0.03
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Axillary brachial plexus block (Procedure)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Cork University Hospital
- Primary completion
- Mar 2016
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Onset of Axillary Block |
8.75; 6.25 | 0.03 sig |
| SECONDARY Duration of Sensory and Motor Block |
165.1; 150.9 | 0.02 sig |
| SECONDARY Block Performance Data- Imaging Time |
2.5; 2.4 | 0.70 |
| SECONDARY Needling Time |
8.5; 6.7 | 0.002 sig |
| SECONDARY Performance Time |
10.9; 9.1 | 0.001 sig |
| SECONDARY No of Needle Pass |
10.5; 9.1 | 0.001 sig |
| SECONDARY Vascular Puncture |
2; 1 | 0.53 |
| SECONDARY Parasthesia |
4; 2 | 0.48 |
Summary
We propose to compare the effects of local anaesthetic dilution on the characteristics of the ultrasound guided axillary brachial plexus block.
Administration of 40ml lidocaine 1% with epinephrine will shorten the onset time of ultrasound guided axillary brachial plexus block when compared to 20 mL lidocaine 2% with epinephrine for elective upper limb surgical procedures.
Eligibility Criteria
Inclusion Criteria
- ASA 1-3
- Patients aged >18 years undergoing elective upper limb (forearm or hand) surgical procedures.
Exclusion Criteria
- Contraindications to regional anaesthesia
- Hypersensitivity to amide local anaesthetics.
- Chronic pain
- Language barrier
- Neuromuscular disorders or peripheral neuropathy
- Body mass index > 35
- History of hepatic and renal insufficiency
- Pregnancy
- Cognitive or psychiatric disorder
- Cardiac conduction abnormality.
Data sourced from ClinicalTrials.gov (NCT03207035). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.